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Abstract
Background: Fibrates correct the typical lipid abnormalities of type 2 diabetes mellitus, yet no
study, to date, has specifically set out to evaluate the role of fibrate therapy in preventing
cardiovascular events in this setting.
Methods:  Subjects with type 2 diabetes, aged 50–75 years, were screened for eligibility to
participate in a long-term trial of comicronized fenofibrate 200 mg daily compared with matching
placebo to assess benefits of treatment on the occurrence of coronary and other vascular events.
People with total cholesterol levels 3.0–6.5 mmol/L plus either a total-to-HDLc ratio >4.0 or
triglyceride level >1.0 mmol/L with no clear indication for lipid-modifying therapy were eligible.
Results: A total of 9795 people were randomized into the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) trial. All received dietary advice, followed by a 6-week single-blind
placebo run-in, then a 6-week active run-in period before randomization. Participants are being
followed up every 6 months for outcome events and safety assessments. The study is designed to
yield at least 500 coronary events (primary endpoint: first nonfatal myocardial infarction or
coronary death) over 5 years, to have 80% power to identify as statistically significant at 2P = 0.05
a 22% reduction in such events, using intention-to-treat methods.
Conclusions:  Type 2 diabetes is the most common endocrine disorder worldwide, and its
prevalence is increasing. The current evidence about use of fibrates in type 2 diabetes, from around
2000 people treated, will increase with FIELD to evidence from around 12000. FIELD will establish
the role of fenofibrate treatment in reducing cardiovascular risk in people with type 2 diabetes. The
main results are expected to be available in late 2005.
Introduction
Type 2 diabetes mellitus is an increasingly common con-
dition associated with a high cardiovascular risk. To date,
very few trials of lipid-lowering therapy have focused on
this condition, and in particular, no large trials of fibrate
therapy in diabetes have been conducted. As fibrates are
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known to correct the typical dyslipidaemia of diabetes,
their role in cardiovascular risk reduction in diabetes may
be especially important. The Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study is a multicen-
tre, double-blind, placebo-controlled trial evaluating the
effects on coronary morbidity and mortality of long-term
treatment with fenofibrate to elevate high-density lipo-
protein (HDL) cholesterol levels and lower triglyceride
(TG) levels in patients with type 2 diabetes and total
blood cholesterol between 3 and 6.5 mmol/L (115 and
250 mg/dL) at study entry. In type 2 diabetes, rates of cor-
onary heart disease (CHD) are 3 to 4 times higher than
those of persons without diabetes at any given level of
blood cholesterol, and at any given age [1,2]. Evidence
also suggests that in women with diabetes the natural pro-
tection against CHD afforded by sex may be lost [3,4].
Further, people with type 2 diabetes have both higher in-
hospital mortality after myocardial infarction (MI) and a
poorer outcome in the subsequent years [5,6], losing on
average between 5 and 10 years of life expectancy. It fol-
lows that type 2 diabetes contributes significantly to the
overall burden of premature CHD morbidity and mortal-
ity, far in excess of its prevalence in the community.
Diabetes and blood lipids
Blood total cholesterol levels are not substantially differ-
ent between patients with type 2 diabetes and those of
nondiabetic populations of similar age and sex [7]. How-
ever, evaluation of other lipoprotein fractions shows that
those with diabetes more often have a below-average HDL
cholesterol level and elevation of TG levels in the blood
[8,9], which together confer an independent additional
risk of CHD [10,11]. Furthermore, although low-density
lipoprotein (LDL) cholesterol levels are not substantially
raised, the LDL particle is often smaller and denser than in
similar nondiabetic populations, which is considered to
be a more atherogenic state [12]. An increased number of
LDL particles, as seen in diabetes, is reflected in an ele-
vated level of plasma apolipoprotein B, a more powerful
predictor of risk for cardiovascular events than either total
cholesterol or LDL cholesterol [13].
The strength of the cholesterol-CHD relationship is very
similar for those with type 2 diabetes as for nondiabetics,
although at a higher background rate of CHD [2]. Evi-
dence from the Helsinki Heart Study [14], which tested
long-term fibrate (gemfibrozil) use in hypercholesterolae-
mic men and women without prior coronary disease,
showed a significant reduction in coronary events, with
the reduction among the small numbers of people with
diabetes not being separately significant, but appearing
somewhat greater [15]. The reductions in events observed
were greater than would have been expected on the basis
of lowering of LDL cholesterol alone. So, whether sub-
stantially increasing low HDL cholesterol levels and
reducing elevated triglyceride levels independently
reduces cardiovascular events and mortality and should
be a specific target for therapy remains less well agreed.
Why a large trial of fibrates?
For patients with type 2 diabetes and its typical dyslipidae-
mia, many physicians believe that fibrates are the logical
first choice of drug treatment. The fibrates have been in
clinical use for a long time, being well tolerated and with
few short-term side-effects. Fenofibrate has been widely
used and marketed for more than 20 years and is an effec-
tive agent for reducing plasma triglyceride and raising
HDL cholesterol [16]. Although the effects on lipid frac-
tions may vary with the population under study, a fall of
15% or more in total cholesterol, mediated through a
reduction in LDL cholesterol, is often seen with long-term
use [16]. In parallel, HDL cholesterol elevation of 10–
15% is common, together with large reductions in plasma
triglycerides of 30–40%. In addition, a reduction in
plasma fibrinogen of about 15% has been observed [16].
FIELD is designed to provide the first properly rand-
omized evidence as to whether the substantial effects of
fenofibrate confer a benefit on clinical cardiovascular
events in persons with type 2 diabetes. A clearly favoura-
ble result might be expected to help physicians determine
which type of lipid-modifying drug therapy is likely to be
most cost-effective for such people.
The FIELD study design
FIELD is a randomized, double-blind, placebo-controlled
parallel-group trial among middle-aged to elderly people
with type 2 diabetes mellitus considered to be at increased
risk of CHD. Those with and without pre-existing vascular
disease or other lipid abnormalities, such as low HDL
cholesterol and elevated TG, were eligible, provided the
total blood cholesterol level at screening fell between 3.0
and 6.5 mmol/L (about 115–250 mg/dL) plus either a
total-to-HDL cholesterol ratio of >4.0 or a blood TG level
>1.0 mmol/L (88.6 mg/dL) (Table 1). The study is being
conducted in 63 clinical centres in Australia (39), Finland
(9) and New Zealand (15) (see Appendix).
The underlying principle guiding recruitment of patients
into the study was that of clinical uncertainty: that is,
patients were only to be considered if the patients' treating
physicians were substantially uncertain about the value of
lipid-modifying therapy for that particular individual and
felt that there was no indication for lipid-modifying ther-
apy. Therefore, none of the participants was on lipid-low-
ering therapy at study entry.
Following clinical and laboratory screening for eligibility,
informed consent, and completion of the run-in period,
patients were randomized to receive either fenofibrateCardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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(200 mg comicronized formulation) or matching placebo
as one capsule daily with breakfast. There was no formal
restriction on randomization related to compliance dur-
ing the run-in period. Randomization was carried out
using a dynamic allocation method [17] with stratifica-
tion for important prognostic factors, including age, sex,
prior MI, lipid levels and urinary albumin excretion. All
patients are being followed up through regular clinic visits
to a clinic set in place for the purposes of the study as well
as by routine health care provided by a regular diabetes
clinic or specialist.
The run-in phase for the study consists of a 4-week diet-
only period, followed by a 6-week single-blind placebo
period, then a 6-week single-blind active run-in period on
comicronized fenofibrate 200 mg once daily for all
patients, before randomization (Figure 1). This was to
allow patients time to discuss long-term participation
with their families and their usual doctors and for evalua-
tion of the benefits of fenofibrate treatment on a back-
ground of recommended dietary advice. Further, the
active run-in period was to determine to what extent any
long-term clinical benefits of treatment correlate with the
short-term effects of the drug to modify different lipid
fractions.
Follow-up in the study will be for not less than 5 years of
median duration and until a total of at least 500 first cor-
onary events have accumulated in the trial, unless the
study is terminated earlier by advice from the Safety and
Data Monitoring Committee.
Study outcomes
The principal study outcome is the combined incidence of
first nonfatal MI or CHD death among all randomized
patients during the scheduled treatment period (Table 2).
Secondary outcomes include the effects of comicronized
fenofibrate on major cardiovascular events (CHD events,
total stroke and other cardiovascular death combined),
total cardiovascular events (major cardiovascular events
plus coronary and carotid revascularization), CHD death,
total cardiovascular deaths, haemorrhagic and nonhaem-
orrhagic stroke, coronary and peripheral revascularization
procedures, cause-specific non-CHD mortality (including
cancer, suicide), and total mortality. All deaths, possible
MIs and possible strokes are adjudicated in blinded fash-
ion by the Outcomes Assessment Committee.
Tertiary outcomes include the effects of treatment on
development of vascular and neuropathic amputations,
nonfatal cancers, the progression of renal disease, laser
treatment for diabetic retinopathy, hospitalization for
angina pectoris, and numbers and duration of all hospital
admissions. The effects of treatment on the outcome of
total cardiovascular events will be examined inThe rates of
events various subgroups of particular interest, such as
men and women, those <65 years and ≥  65 years of age,
by subgroup of each of baseline total cholesterol, HDL
Table 1: Inclusion and exclusion criteria for the FIELD study
Individuals were eligible for this study provided they had the following characteristics:
• male or female, aged 50–75 years inclusive
• non-insulin dependent diabetes mellitus (type 2) with age at diagnosis >35 years (currently using any of diet, tablets or insulin); for Maori, Pacific 
Islanders, Australian Aborigines and Torres Strait Islanders, the eligible age of diagnosis was >25 years, provided there had been at least 1 year of 
treatment without insulin
• on the basis of diabetes, considered to be at higher risk for coronary heart disease than the general population
• no clear indication for any cholesterol-lowering treatment: the patient was not already taking any cholesterol-lowering drug and neither the 
patient nor the patient's doctor considered there to be any definite need to do so
• total cholesterol level 3 to 6.5 mmol/L, plus either
a total cholesterol-to-HDL cholesterol ratio of ≥  4.0
a blood triglyceride level >1.0 mmol/L
• no clear contraindication to study therapy in the view of the treating physician
• no other predominant medical problem that might limit compliance with 5 years of study treatment or compromise long-term participation and 
clinic attendance in the trial
Individuals were not eligible if they had any of the following characteristics:
• serum triglyceride >5 mmol/L in the baseline visit fasting blood sample
• concurrent treatment with any other lipid-lowering agent
• serum creatinine >130 µmol/L
• known chronic liver disease, transaminases >2 × upper limit of normal or symptomatic gall-bladder disease
• myocardial infarction or hospital admission for unstable angina within 3 months
• female, of child-bearing potential, unless sterilized or on reliable approved methods of contraception, including oral contraceptives
• concurrent cyclosporin treatment (or a condition likely to result in organ transplantation and the need for cyclosporin during the next 5 years)
• known allergy to any fibrate drug or known photosensitivity
• unwilling or unable to consent to enter the study, with the understanding that follow-up was planned to continue for more than 5 yearsCardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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cholesterol, triglyceride and fibrinogen, baseline insulin
use, or not, and the presence, or absence, at baseline of
microalbuminuria.
The primary analysis will be of time to first study out-
come, using standard log-rank methods [18,19], and
where appropriate, proportional-hazards models with
adjustment for covariates. Intention-to-treat methods,
comparing all those allocated to comicronized fenofibrate
with all those allocated to placebo, will be used.
Sample size
The rates of events used for the original study power cal-
culations were based on information from a variety of
sources. During recruitment, when the numbers of partic-
ipants with prior MI was falling well short of the number
Study flow schema Figure 1
Study flow schema. CVD = cardiovascular disease.
Follow-up in clinic 6-monthly for study outcomes and any adverse events 
until median of 5 years follow-up or 500 major CHD events have occurred 
Invitation to register 
Visit 1: screening in clinic — those willing and 
clinically eligible identified 
Visit 4: random allocation of eligible patients 
without interceding CVD event
Visit 2: laboratory-eligible patients identified 
Visit 3: willing and eligible patients without 




placebo run-in phase 
6-week single-blind 
active run-in phase on 
fenofibrate 200 mg 
daily
Comicronized fenofibrate 
200 mg daily for average of 
5 years 
Matching placebo capsule 
daily for average of 5 years 
Table 2: Definitions for primary outcome assessment in the 
FIELD study
Myocardial infarction
Definite myocardial infarction = criterion 1; or any two of criteria 2 to 
4; or criterion 5
1. New Q waves: new pathological Q waves (or Q-S pattern) of at 
least 0.03 seconds in width in at least 2 leads in the same lead group 
(in the absence of left bundle branch block)
2. Evolutionary ST-T wave changes: evolution of an injury current 
lasting more than one day and present in at least 2 leads in the same 
lead group: for example, ST elevation of 2 mm or more in anterior 
leads, or 1 mm or more in inferior leads followed by T-wave inversion 
of 1 mm or more; this requires a minimum of two traces taken at 
least one day apart
3. Ischemic pain: history of typical ischemic pain lasting for at least 15 
minutes and unresponsive to sublingual nitrates (if given)
4. Biochemical markers: elevation of CK or CKMB enzymes to over 
twice the upper limit of normal (for the laboratory) after the attack or 
elevation of troponin T to more than 0.1 µg/L or troponin I to levels 
above the upper limit of normal (for the laboratory)
5. Postmortem diagnosis: autopsy showing evidence of acute 
myocardial infarction.
Death
Coronary heart disease death = any of 1.1 to 1.7
1. Coronary
1.1 Definite fatal myocardial infarction: death following definite acute 
myocardial infarction in the preceding 28 days (and without an 
unrelated noncoronary cause of death), or autopsy-proven recent 
acute myocardial infarction
1.2 Sudden cardiac death: death occurring within one hour of onset of 
new cardiac symptoms or unwitnessed death after last having been 
seen without new symptoms; in each case, without any noncoronary 
disease that could have been rapidly fatal and without having been 
confined to hospital or other institution because of illness within 24 
hours of death
1.3 Possible myocardial infarction: death in hospital with possible 
myocardial infarction (that is, typical ischaemic pain and ECG and 
enzyme results do not fulfil the criteria for definite myocardial and 
there is no good evidence for another event)
1.4 Resuscitated sudden death: documented cardiac arrest (in or out 
of hospital), after being resuscitated from what would have been 
sudden death; patient lives for more than one hour (hours to weeks).
1.5 Heart failure: death due to heart failure (prior grade 3–4 
dyspnoea, NYHA) without any defined noncoronary cause
1.6 Death after coronary revascularisation: death (in the same 
admission) after any coronary revascularisation procedure (CABG or 
PTCA).
1.7 Other coronary: death where the underlying cause is certified as 
coronary (and there is no evidence for a noncoronary cause of death, 
clinically or at autopsy)
2. Noncoronary cardiac: death for which the underlying cause is 
certified as noncoronary cardiac disease
3. Vascular (noncardiac): death which is certified as vascular but not 
coronary disease: for example, cerebrovascular accident, pulmonary 
embolism, complications of peripheral vascular disease or 
uncontrolled hypertension
4. Cancer: death for which the underlying cause is certified as 
malignant neoplasm
5. Trauma: death where the underlying cause is certified as a wound 
or injury either accidental or inflicted
6. Suicide: death for which the underlying cause is certified as 
deliberate and voluntary taking of one's own life
7. Other: other cause of death not specified above.Cardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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originally planned (in about 2000), the sample size was
extended from the original total of 8000 to a final number
of 9795 reached in November 2000. In late 2002, the sta-
tistical power of the trial was reviewed again. These
reviews were planned in the original protocol design and
were undertaken by reviewers completely blinded to all
treatment allocation. The reassessment included informa-
tion on final sample size, overall rate of discontinuation
of study medication and commencement of open-label
cholesterol treatment, and overall event rates in relation
to CHD death, MI, and stroke.
After the review it was clear that the trial would yield too
few deaths from CHD to retain sufficient power, over its
planned duration of around 5 years, to show a significant
reduction in this endpoint. The FIELD Management Com-
mittee determined that the primary outcome of the trial
should be amended from CHD death to CHD events (that
is, CHD death plus nonfatal MI, a decision made in
December 2002). It was also decided to change the prin-
cipal outcome for subgroup analyses to look at the effects
of fenofibrate in subjects with and without prior cardio-
vascular disease (CVD) (originally those with and without
prior MI).
For a primary outcome of CHD events (CHD death plus
nonfatal MI), it is projected that approximately 500 CHD
events will have occurred when 5 years median follow-up
has elapsed (during the first quarter of 2005); by this time
the trial will have 80% power to detect an observed 22%
reduction in CHD events (based on the intention-to-treat
method of analysis). This will also provide 90% power to
detect a 25% relative reduction in CHD events (based on
intention-to-treat analysis). Both calculations allow for
the effects of an average drop-out rate from active treat-
ment over the course of the study of 10% and a similar
drop-in rate of 10% from placebo to open cholesterol-
lowering therapy (Table 3). These allowances for loss of
compliance require an increase in sample size of approxi-
mately 60% when compared with a study with no drop-
outs from, or drop-ins to, active treatment.
If the uptake of cholesterol-lowering therapy proves to be
greater in the placebo group than in the fenofibrate-allo-
cated group, the observed treatment effect of fenofibrate
will underestimate its true efficacy.
Safety and event monitoring
The trial has an independent Safety and Data Monitoring
Committee to safeguard the patients' interests and to for-
mally evaluate from time to time on a regular basis
whether, for any reason, they would recommend that the
study should be modified or stopped. Up to 5 formal
interim analyses are planned, at time points to be deter-
mined by the Safety and Data Monitoring Committee,
with a stringent nominal significance level (3 standard
deviations; 2P = 0.003) to preserve an overall type 1 error
probability of no more than 0.05. The events to be used
for these analyses are counts of death from CHD. The
Management Committee, the collaborators, the study
sponsor and all the central administrative staff, with the
exception of the unblinded statistician, will remain igno-
Table 3: Predicted numbers of events and corresponding power in the FIELD study among 9795 people with diabetes, based on a 
median follow-up of 5 years
Allocated treatment Power to detect effect 
at 2P < 0.05*
Risk category Fenofibrate Placebo
Primary prevention (7683 with no prior CVD)
Total CVD events† 298 385 93%
Secondary prevention (2112 with prior CVD)
Total CVD events 229 288 83%
Men (6139)
Total CVD events 392 503 98%
Women (3656)
Total CVD events 133 171 60%
All patients (9795)
Total CVD events 525 675 99%
Total CHD events 219 281 80%
* Calculations assume a reduction in risk for each endpoint of around 27% with full compliance, resulting in an observed risk reduction of 
approximately 22% on intention-to-treat analysis; the risk in the prior CVD group is 2.75 times that for patients with no prior CVD, the risk in men 
is 1.75 times that in women.
† Expanded endpoint 'total CVD events' comprises cardiovascular death, nonfatal myocardial infarction, coronary artery bypass grafting, 
percutaneous transluminal coronary angioplasty, stroke and carotid revascularization.
CVD = cardiovascular, CHD = coronary heart diseaseCardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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rant of the interim results for mortality and major mor-
bidity. During the study, the group effects of treatment on
biochemical parameters, such as lipid fractions, and other
surrogate endpoints may be published, subject to prior
approval of the Management Committee, provided that
individual patient treatment assignments are not revealed.
Patients are being monitored regularly by lipid profiles,
liver function tests, creatine phosphokinase, fasting glu-
cose, HbA1c, and urinary microalbumin. The study has
been approved by local ethics committees at each partici-
pating institution, which also approved the information
discussed and informed-consent procedures. The first
patient in FIELD was registered in November 1997 and
randomized in February 1998. The study has recruited
9795 patients; the final patient was randomized on 3
November 2000.
Study sponsorship and organisation
The main sponsor of the trial and supplier of the fenofi-
brate and matching placebo medication, is Laboratoires
Fournier S.A., Dijon, France. The study is also supported
by the National Health and Medical Research Council of
Australia through Unit, Program and Fellowship grants to
the NHMRC Clinical Trials Centre. The study is being
coordinated independently of the sponsors by the
NHMRC Clinical Trials Centre, University of Sydney, Syd-
ney, Australia and overseen by the study Management
Committee. The study has been endorsed by the National
Heart Foundation of Australia, Diabetes Australia, the
New Zealand Society for the Study of Diabetes, and the
Finnish Diabetes Association.
Conclusion
In 1997, before the FIELD study commenced, the role of
lipid modification in diabetes remained uncertain, except
possibly for hypercholesterolaemic people with a prior
MI. Two large-scale trials, the Scandinavian Simvastatin
Survival Study (4S) [20] and the Cholesterol and Recur-
rent Events (CARE) [21] study, had showed that the use of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors, simvastatin and pravastatin, respec-
tively, substantially reduced cardiovascular events hyperc-
holesterolaemic and in general post-MI populations. But
neither study included sufficient numbers of patients with
diabetes (n = 202 and n = 586, respectively) to have the
power to show reliably whether these benefits would
translate into reductions in CHD mortality in the setting
of diabetes, nor the effects in them of treatment on
noncoronary events and mortality. Further, the West of
Scotland (WOSCOPS) study of pravastatin in hypercho-
lesterolaemic men with no prior CHD, which reported a
marginally significant reduction in overall mortality, had
fewer than 100 subjects with diabetes [22].
Since that time, numerous other trials of statin treatment
have been reported, with randomized data now reported
on over 18000 persons with diabetes. Those involving
more than 1000 people with diabetes include the Long-
Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) study [6,23], the Heart Protection Study [24,25],
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
[26] and Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT-LLT) [27]. Another
trial, the Collaborative Atorvastatin Diabetes Study
(CARDS), has stopped early, after about 4 years of follow-
up, with results showing clear benefits of reduced cardiac
and stroke events of using atorvastatin among 2838 peo-
ple with diabetes and high cardiovascular risk [28].
Important new results have been communicated to inves-
tigators and patients so that it can be considered whether,
during the follow-up of FIELD, statin therapy is now indi-
cated for any individual. The protocol allows for statin
therapy to be added at any time after randomization and
recommends continuing study medication; thus the study
is evaluating the role of fenofibrate on a background of
usual care. This feature of the study design will contribute
to the evidence about the safety of combined statin and
fibrate therapy.
Two large-scale trials of fibrate therapy have also been
completed: the Veterans Low-HDL Cholesterol Interven-
tion Trial (VA-HIT) [29,30] and the Bezafibrate Infarct
Prevention (BIP) [31] trial. Both studies were limited to
people with prior MI and have reported reductions in
major cardiovascular events among participants with low
HDL and high TG at baseline, which were greater than
those seen with use of the same fibrate among those with-
out dyslipidaemia. The VA-HIT trial also reported reduced
CHD mortality in those with diabetes receiving gemfibro-
zil and a reduced rate of cardiovascular events, although
rates of nonfatal MI did not change significantly [32]. A
third trial, the Diabetes Atherosclerosis Intervention Study
(DAIS), showed reduced progression of established coro-
nary atherosclerosis among those randomized to fenofi-
brate compared with those receiving matching placebo,
over 3 years [33].
At the same time, our understanding of the mechanism of
action of fibrates has grown, with identification of the per-
oxisome proliferator-activated receptor alpha (PPAR-
alpha) transcription factor as the primary pathway
through which fibrate-mediated effects are triggered
[34,35]. The abundance of desirable effects of PPAR-alpha
activation by fibrates has generated extraordinary interest
in their role in the prevention of atherosclerosis via regu-
lation of lipid metabolism, vascular inflammation, and
haemostatic factors. The importance of changes in apoli-
poprotein B and non-HDL-cholesterol levels appears
greater with fibrate therapy than with statin use [36], par-Cardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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ticularly in patients with type 2 diabetes [37]. Increased
interest in the FIELD study has resulted, as it will generate
clinical data on similar numbers of persons with diabetes
to that available for the statins (Table 4) and will enlarge
the range of lipid profiles studied and the number of
events in such populations (Table 5).
Table 4: Unconfounded randomized controlled trials of lipid-lowering therapy, showing numbers of subjects with diabetes
Study Population Year of primary 
publication
Therapy Total no. No. with 
diabetes
Reference
4S Prior CHD 1994 Simvastatin 20–40 mg 4444 202 20, 38
CARE Prior CHD 1996 Pravastatin 40 mg 4159 586 21
Post-CABG* Prior CHD 1997 Lovastatin 40–80 mg vs 2.5–5 mg 1351 122 39, 40
LIPID Prior CHD 1998 Pravastatin 40 mg 9014 1077 6, 23
GISSI-P* Prior CHD 2000 Pravastatin 20 mg 4271 582 41
GREACE* Prior CHD 2002 Atorvastatin 10–80 mg 1600 313 42
PROSPER Mixed 2002 Pravastatin 40 mg 5804 623 43
ALLHAT-LLT* Mixed 2002 Pravastatin 20–40 mg 10355 3638 27
HPS Mixed 2003 Simvastatin 40 mg 20536 5963 24, 25
ASCOT-LLA Mixed 2003 Atorvastatin 10 mg 10305 2532 26
WOSCOPS Primary 1995 Pravastatin 40 mg 6595 76 22
AFCAPS/TexCAPS Primary 1998 Lovastatin 20–40 mg 6605 1 55 44
CARDS Primary 2004 Atorvastatin 10 mg 2838 2838 28
Total – – Any statin 87877 18707
VA-HIT Prior CHD 1999 Gemfibrozil 1200 mg 2531 769 29, 30, 32
BIP Prior CHD 2000 Bezafibrate 400 mg 3090 309 31
DAIS Mixed 2001 Fenofibrate 200 mg 418 418 33
LEADER Mixed 2002 Bezafibrate 400 mg 1568 268 45
SENDCAP Primary 1998 Bezafibrate 400 mg 164 164 46
HHS Primary 1992 Gemfibrozil 1200 mg 4081 135 14, 15
Total – – Any fibrate 11852 2063
* No placebo used; lipid lowering compared with less treatment in Post-CABG study, with no treatment in GISSI-P study, and with usual care in 
ALLHAT-LLT and GREACE studies.
CHD = coronary heart disease
Table 5: Entry criteria and outcomes in trials of fibrates
Study Demographic entry criteria Lipid entry criteria Outcomes
SENDCAP men and women, 35–65 years, no 
cardiovascular disease
• serum cholesterol ≥  5.2 mmol/L
• triglyceride ≥  1.8 mmol/L
• HDL ≤  1.1 mmol/L
• total/HDL ≥  4.7
change in carotid intima-media 
thickness, lipid changes, CHD events, 
at 3 years
VA-HIT men, <74 years, documented 
history of CHD
• HDL ≤  1.0 mmol/L
• LDL ≤  3.6 mmol/L
• triglyceride ≤  3.4 mmol/L
nonfatal MI or CHD death over 
median 5.1 years
BIP men and women, 45–74 years, MI 
6 months to 5 years before, no 
insulin-dependent diabetes
• serum cholesterol 4.7-6.5 mmol/L
• LDL ≤  4.7 mmol/L
• HDL ≤  1.2 mmol/L
• triglyceride ≤  3.4 mmol/L
fatal or nonfatal MI or sudden death 
over mean 6.2 years
DAIS men and women, 40–65 years, 
type 2 diabetes
• total/HDL ≥  4
• LDL 3.5–4.5 mmol/L + triglyceride ≤  5.2 mol/L 
or LDL ≤  4.5 mmol/L + triglyceride 1.7–5.2 mol/L
change in coronary artery lumen 
diameters, by angiography, and lipid 
changes after 3 years
LEADER men with lower-extremity arterial 
disease, no lipid-lowering drug
• serum cholesterol 3.5–8.0 mmol/L CHD events and stroke over median 
4.6 years
HHS men, 40–55 years, asymptomatic • non-HDL cholesterol >5.2 mmol/L lipid changes, MI, cardiac death at 5 
years
CHD = coronary heart disease, MI = myocardial infarction, HDL = high-density lipoprotein, LDL = low-density lipoproteinCardiovascular Diabetology 2004, 3:9 http://www.cardiab.com/content/3/1/9
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Approximately 140 million adults were estimated to be
suffering from diabetes mellitus, the most common endo-
crine disorder worldwide, in 1997. By 2010, projections
put diabetes prevalence about 60 percent higher, at 221
million. Just as many persons again have an elevated fast-
ing glucose level, or impaired fasting glucose, which can
progress rapidly to diabetes. Without the FIELD study,
doctors would remain uncertain about the merits of using
a fibrate when confronted with a patient with diabetes at
risk of clinical CHD. It is expected that the main results of
FIELD will be reported in late 2005.
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